In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
After Roche released initially reassuring datasets for its wet AMD and DME candidate, BTIG’s Dane Leone believes this spells trouble for REGN.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have excited investors with key clinical moves forward for the firms, between VRTX’s double …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (NYSE:SNY) announced that the FDA approved DUPIXENT® (dupilumab) Injection, the first and only biologic medicine approved for …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that they will appeal the injunction granted today by the U.S.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Jay Markowitz, M.D.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Geisinger Health System (Geisinger) today announced that Science has published a paper describing how the DiscovEHR collaboration between …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for …
The biotech world is buzzing after a criminal charge-laden press release has circled the name of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Regeneron Pharmaceuticals …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the ongoing Praluent® (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of …